BNP Paribas Financial Markets Sells 48,659 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

BNP Paribas Financial Markets reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 38.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 79,171 shares of the medical research company's stock after selling 48,659 shares during the quarter. BNP Paribas Financial Markets owned about 0.15% of Charles River Laboratories International worth $15,594,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Quantbot Technologies LP bought a new position in Charles River Laboratories International in the 3rd quarter valued at about $1,609,000. Truvestments Capital LLC increased its holdings in Charles River Laboratories International by 17.0% in the 3rd quarter. Truvestments Capital LLC now owns 2,407 shares of the medical research company's stock valued at $474,000 after buying an additional 350 shares during the period. Fisher Asset Management LLC increased its holdings in Charles River Laboratories International by 0.9% in the 3rd quarter. Fisher Asset Management LLC now owns 184,692 shares of the medical research company's stock valued at $36,379,000 after buying an additional 1,586 shares during the period. Daiwa Securities Group Inc. increased its holdings in Charles River Laboratories International by 12.6% in the 3rd quarter. Daiwa Securities Group Inc. now owns 6,355 shares of the medical research company's stock valued at $1,252,000 after buying an additional 710 shares during the period. Finally, Cerity Partners LLC increased its holdings in Charles River Laboratories International by 65.9% in the 3rd quarter. Cerity Partners LLC now owns 4,891 shares of the medical research company's stock valued at $963,000 after buying an additional 1,943 shares during the period. 98.91% of the stock is owned by institutional investors.

Insider Transactions at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.30% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on CRL shares. The Goldman Sachs Group decreased their price target on shares of Charles River Laboratories International from $290.00 to $250.00 and set a "buy" rating on the stock in a report on Thursday, August 8th. Barclays decreased their price target on shares of Charles River Laboratories International from $230.00 to $210.00 and set an "equal weight" rating on the stock in a report on Thursday, August 8th. TD Cowen lifted their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a report on Monday, November 11th. UBS Group lifted their price target on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Finally, Robert W. Baird decreased their price target on shares of Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating on the stock in a report on Friday, September 20th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Charles River Laboratories International has an average rating of "Hold" and a consensus price target of $214.38.

Charles River Laboratories International Trading Down 0.3 %

Shares of NYSE CRL traded down $0.53 during midday trading on Friday, reaching $199.06. The stock had a trading volume of 287,759 shares, compared to its average volume of 780,522. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. Charles River Laboratories International, Inc. has a twelve month low of $176.48 and a twelve month high of $275.00. The company's 50 day moving average price is $194.32 and its 200 day moving average price is $204.75. The firm has a market cap of $10.18 billion, a price-to-earnings ratio of 24.91, a price-to-earnings-growth ratio of 5.13 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating analysts' consensus estimates of $2.43 by $0.16. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. Charles River Laboratories International's quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.72 EPS. As a group, sell-side analysts expect that Charles River Laboratories International, Inc. will post 10.19 EPS for the current year.

Charles River Laboratories International announced that its Board of Directors has initiated a share repurchase program on Wednesday, August 7th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 9.6% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's management believes its stock is undervalued.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).